Last reviewed · How we verify

NCT03451448

PET MRI in Coronary Artery Disease

Completed Last updated 21 May 2024
What this trial tests

trial testing PET/MRI in Coronary Artery Disease in 16 participants. Completed in 31 January 2024.

Timeline
1 February 2018
Primary endpoint
1 May 2023
31 January 2024

Quick facts

Lead sponsorUniversity of Edinburgh
StatusCompleted
Study typeOBSERVATIONAL
Enrollment16
Start date1 February 2018
Primary completion1 May 2023
Estimated completion31 January 2024
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

University of Edinburgh

Who can join

40 and older, any sex, with Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will assess the use of position emission tomography/magnetic resonance imaging (PET/MRI) using ultra-small-superparamagnetic particles of iron oxide (USPIO) as a contrast agent in patients with coronary artery disease.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Imaging Constructs: The Rise of Iron Oxide Nanoparticles.
    Crețu BE, Dodi G, Shavandi A, Gardikiotis I, et al · · 2021 · cited 18× · PMID 34198906 · DOI 10.3390/molecules26113437
  2. Nanoparticle-Based Activatable Probes for Bioimaging.
    Ma T, Xia T. · · 2021 · cited 6× · PMID 33724732 · DOI 10.1002/adbi.202000193

Verify or expand the search:

Other trials of PET/MRI

Trials testing the same drug.

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

Other University of Edinburgh trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03451448.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing